News

Technology News

Apogee Biotechnology Launches Phase I Studies

Wednesday, November 10, 2010 5:01:00 AM PDT | VentureDeal Staff
  Hershey, Pennsylvania  --  Apogee Biotechnology Corporation is poised to begin Phase I clinical trials of its first in class sphingosine kinase inhibitor.

Apogee received Food and Drug Administration approval of its Investigational New Drug (IND) application.

Sphingosine kinase controls the growth of tumors by promoting cancer cell proliferation, inflammation and new blood vessel formation.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1